Hintergrund: In dieser Anwendungsbeobachtung wird zum ersten Mal die Behandlung des Reizdarmsyndroms (RDS) mit einem homöopathisch-phytotherapeutischen Komplexpräparat beschrieben. Methodik: Ziel der 6-wöchigen Therapie mit dem Magen-Darm-Entoxin N® war die Reduzierung der RDS-Symptomatik sowie die Verbesserung der Lebensqualität. Zielkriterien waren die Veränderungen in der Irritable Bowel Syndrome - Severity Scoring System (IBS-SSS) und der Irritable Bowel Syndrome - Quality-of-Life Scale (IBS-QoL). Die Patient/innen (N = 41; Alter 44,0 ± 15,74 Jahre) wurden zu gleichen Teilen in einer Hausarztpraxis (N = 20) und einer Heilpraktikerpraxis (N = 21) rekrutiert. Ergebnisse: Der IBS-QoL-Score verringerte sich signifikant (prä: 35,9 ± 16,3; post: 20,1 ± 13,4; t = 8,504; p < 0,001). Die Effektstärke betrug 1,34 (Cohens d). Der IBS-SSS-Score verringerte sich ebenfalls signifikant (prä: 239,4 ± 83,4; post: 123,7 ± 80,9; t = 7,825; p < 0,001) mit einer Effektstärke von d = 1,24. Die Neben- und Wechselwirkungen waren minimal und signifikante Unterschiede zwischen beiden Praxen wurden nicht gefunden. Schlussfolgerungen: Magen-Darm-Entoxin N® ist eine sichere und sinnvolle Therapieoption bei der Behandlung des RDS. Allerdings sollten randomisierte kontrollierte Studien folgen, um die Spezifizität der Ergebnisse dieser Anwendungsbeobachtung zu stützen.

Keywords:
Homöopathie, Phytopharmazie, Reizdarmsyndrom, Magen-Darm-Entoxin N®, Anwendungsbeobachtung
1.
Müller-Lissner SA, Pirk O: Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002;14:1325-1329.
2.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, et al: Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22:935-942.
3.
Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, et al: [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011;49:237-293.
4.
Uehleke B, Zahradnicek S, Vennos C: [The Tibetan formula Padma Lax in medical practice: a retrospective case series study in constipation including 174 patients]. Forsch Komplementmed 2013;20(suppl 2):8-13.
5.
Grundmann O, Yoon SL: Complementary and alternative medicines in irritable bowel syndrome: an integrative view. World J Gastroenterol 2014;20:346-362.
6.
Sahib AS: Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol 2013;148:1008-1012.
7.
Ivashkin VT, Poluektova YA: Irritable bowel syndrome: pathophysiological and clinical issues. Russ J Gastroenterol Hepatol Coloproctol 2015;25:4-16.
8.
Ivashkin VT, Mayev IV, Sheptulin A, Trukhmanov AS, Alekseyeva OP, Baranskaya YK, et al: The resolution of Advisory council «How to improve treatment results functional dyspepsia and irritable bowel syndrome»? Russ J Gastroenterol Hepatol Coloproctol 2016;26:101-104.
9.
Nöthen M, Böhm K: Gesundheitsberichterstattung des Bundes. Berlin, Robert Koch-Institut, 2009.
10.
Benno P, Dahlgren A-L, Befrits R, Norin E, Hellström PM, Midtvedt T: From IBS to DBS: the dysbiotic bowel syndrome. J Investig Med High Impact Case Rep 2016;4:2324709616648458.
11.
Benno P, Befrits R, Norin E, Berstad A, Dahlgren A-L, Midtvedt T, et al: Is irritable bowel syndrome a dysbiotic bowel syndrome? Microb Ecol Health Dis 2015;26:27637.
12.
Benno P, Befrits R, Berstad A, Dahlgren A-L, Norin E, Midtvedt T: [Underlying dysbiosis may be the cause of some forms of IBS. Patients were free of symptoms after the administration of microbiota]. Läkartidningen 2015;112.
13.
Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D, et al: Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut 2017;66:980-982.
14.
Fecal microbial transplantation in treatment of irritable bowel syndrome; a double blinded placebo controlled trial. Tromsö, University Hospital of North Norway, 2014. https://clinicaltrials.gov/ct2/show/NCT02154867? term = NCT02154867&rank = 1 (letzter Abruf 15. Mai 2017).
15.
Efficacy/safety study to confirm iberogast's efficacy in Rome-III patients in irritable bowel syndrome. Leverkusen, Bayer, 2013. https://clinicaltrials.gov/ct2/show/ NCT01940848?term = Iberogast&rank = 2 (letzter Abruf 15. Mai 2017).
16.
Kleine R: Die Entoxin Therapie nach Dr. Kleine. Handschriftliche Aufzeichnungen der Tochter Kleines. Bühl, Spenglersan GmbH, Archiv, 1984.
17.
Francis CY, Morris J, Whorwell PJ: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
18.
Betz C, Mannsdörfer K, Bischoff SC: [Validation of the IBS-SSS]. Z Gastroenterol 2013;51:1171-1176.
19.
Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL: Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400-411.
20.
Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al: Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
21.
Bortz J, Schuster C: Statistik für Human- und Sozialwissenschaftler. Berlin, Heidelberg, Springer, 2010.
22.
Bubenzer RH, Kaden M: Monographien Kommission D (Homöopathische Therapierichtung und Stoffgruppe). Heilpflanzen-Welt, http://buecher.heilpflanzen-welt.de/BGA-Kommission-D-Monographien/index.htm (letzter Abruf 15. Mai 2017).
23.
Bundesinstitut für Arzneimittel und Medizinprodukte (ed): Liste der Monographien der E-Kommission (Phyto-Therapie), die im Bundesanzeiger veröffentlich sind. Köln, Bundesanzeiger Verlagsgesellschaft, 2002.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.